



Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer

Ari Nishimura¹ · Akira Ono¹ · Kazushige Wakuda¹ · Takanori Kawabata² · Michitoshi Yabe¹ · Taichi Miyawaki¹ · Eriko Miyawaki¹ · Hiroaki Kodama¹ · Naoya Nishioka¹ · Nobuaki Mamesaya¹ · Haruki Kobayashi¹ · Shota Omori¹ · Hirotsugu Kenmotsu¹ · Tateaki Naito¹ · Haruyasu Murakami¹ · Hideyuki Harada³ · Toshiaki Takahashi¹

Published online: 8 November 2021

© The Author(s) 2021

Correction to: *Investigational New Drugs* <https://doi.org/10.1007/s10637-021-01191-6>

The original version of this article unfortunately contained mistakes which are listed below.

1. Page 3: “The median interval from durvalumab administration until the occurrence or exacerbation of pneumonitis was 39.5 days (range: 14–181 days). The median interval from the completion of CRT to the occurrence or exacerbation of pneumonitis was 64.5 days (range: 19–202 days).” must be deleted.

2. Page 4: Changed to “The pneumonitis developed at a median interval of 2.1 months (range: 0.5–6.0 months) after the completion of radiotherapy and a median of 0.5 months (range: 0.0–2.6 months) after the final dose of durvalumab.”

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10637-021-01191-6>.

✉ Akira Ono
a.ono@scchr.jp

¹ Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan

² Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan

³ Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan